Pharmacyte Biotech Inc (OTCMKTS:PMCB) Is At A Turning Point

In our previous coverage of Pharmacyte Biotech Inc (OTCMKTS:PMCB), we’ve looked at the research and development (R&D) efforts the company is making to create cancer and diabetes therapies to address the unmet treatment needs in these disease areas.In today’s piece, we look at an intriguing development that we believe would have tremendous positive impact on the price of PMCB. This development relates to the hiring of a renowned publicist to help the company with its investor messaging.We’ll look into this in details in a short while, but first take a look at PMCB’s share price action. PMCB Daily ChartBusinessPMCB is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes. The company is basing its drug development work on a proprietary technology called Cell-in-a-Box.In the cancer therapy area, PMCB has made significant progress with the development of a treatment for pancreatic cancer – one of the common causes of cancer deaths in the US, according to the National Center for Biotechnology Information.According to research firm Grand View Research, global pancreatic cancer treatment market will be worth $4.2 billion by 2025. Factors such as smoking, obesity and growing awareness around pancreatic cancer treatment options are fueling the growth of pancreatic cancer treatment market. PMCB, with its ongoing pancreatic cancer therapy program, is a candidate in the multibillion-dollar pancreatic cancer treatment market.Overall, Zion Market Research estimates that cancer treatment market will be worth $161.3 billion by 2021, up from $112.9 billion in 2015. And this is just part of the story because the company is also underway with development of diabetes treatment. According Global Market Insights, global antidiabetics market will be worth $116.1 billion by 2023.PMCB stepping up investor messagingWe’ve been tracking PMCB’s messaging and we recently came across an intriguing announcement that we believe could mark a turning point for the stock. For well over a year, investor relations matters took a backseat at PMCB as the company didn’t have a communications partner to advance its interest in the investment community. But this is changing.On September 13, PMCB announced that it appointed Alan Morell to support its investor messaging efforts. Morell is the chairman and CEO of Creative Management Partners, a media relations firm headquartered California but with officers in New York, Toronto and London. PMCB appointed Morell to the position of strategic advisor to its CEO Kenneth L. Waggoner.Commenting on the appointment of Morell as strategic advisor, Waggoner stated:

“We now have reached the point in our lifecycle as a biotech company where we have a complete story we can finally tell. […] Having Mr. Morell join our team is a unique opportunity for us. It is not one that would have come our way without a long-standing and very personal relationship between Dr. (Leonard) Makowka (our Senior Strategic Advisor) and Mr. Morell. […] It is through his relationships that we believe he will be effective in telling our story and telling it to the right people.”

SourceOn his part, Morell commented that:

“I am extremely honored to join PharmaCyte’s team. It has a serious and impactful story to share – a story that has yet to be told. PharmaCyte is poised to change the way solid cancerous tumors are treated. This is particularly true with one of the deadliest forms of cancer – pancreatic cancer – a cancer that has touched my friends and family. Beyond that, the potential opportunities for growth in cellular therapies using the Cell-in-a-Box technology are virtually limitless.”

SourceMorell is an expert in business management, branding, media strategy, talent management and product licensing. He boasts over 30 years of industry experience. Morell has experience helping companies with developing growth strategy and market positioning. In this area, his work has involved identifying associations for media campaigns, print publications, online publications and social media. Morell works regularly with hundreds of news affiliates, which include major networks such as FOX, CNBC and MSNBC.In its announcement, PMCB said that it expected Morell to place it in front of a host of media outlets. Furthermore, PMCB noted that the professional relationships that Morell brings to the table can lead to unique opportunities for the company to raise capital. Since Morell also represents numerous celebrities in Hollywood and New York, he can expand the audience for PMCB beyond what a traditional investor relations or public relations firm could provide.With the appointment of Morell, we appreciate that PMCB has taken a step that will bring more buyers into the stock thanks to increased investor awareness.Conclusion In conclusion, we note that PMCB has strong financials. Although the company didn’t generate revenue in the most recent quarter (the period ended July 31, 2017), it finished the quarter with $4.3 million in cash, and its assets increased to more than $9.5 million. The company was carrying just $865,000 in total liabilities at the end of the July quarter. The appointment of Morell as strategic advisor and the professional relationships he brings should make it easier for PMCB to raise additional capital in future when needed.We will be updating our subscribers as soon as we know more. For the latest updates on PMCB, sign up below!Disclosure: We have no position in PMCB and have not been compensated for this article.